<?xml version="1.0" encoding="UTF-8"?>
<html><body class="spl" id="spl">
<div class="DocumentTitle"><p class="DocumentTitle"><strong>DICYCLOMINE HYDROCHLORIDE- dicyclomine hydrochloride solution </strong><br>MIKART, INC.<br></p></div>
<h1>DICYCLOMINE HYDROCHLORIDE ORAL SOLUTION USP<br>(10 mg/5 mL)</h1>
<div class="Contents">
<div class="Section" data-sectionCode="48780-1">
<a name="section-1"></a><p></p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_7BDD65C6-DEDE-4D48-A338-FCC299D35B13"></a><a name="section-1"></a><p></p>
<p class="First">Code 814Z00</p>
<p>Rev. 03/08                                                                                                             </p>
<p><span class="Bold">Rx only</span></p>
</div>
<div class="Section" data-sectionCode="34089-3">
<a name="i4i_description_ID_00A05F7E-259B-4F1A-AC3B-7B48728E0DE6"></a><a name="section-2"></a><p></p>
<h1>DESCRIPTION</h1>
<p class="First">Dicyclomine hydrochloride oral solution is an antispasmodic and anticholinergic (antimuscarinic) agent. Each 5 mL (teaspoonful) of Dicyclomine HCl Oral Solution USP for oral administration contains:</p>
<p>Dicyclomine HCl …………………………. 10 mg</p>
<p>Also contains glycerin, methylparaben, propylene glycol, propylparaben, purified water, sorbitol solution, sucrose, with D&amp;C Red #33, FD&amp;C Blue #1, FD&amp;C Red #40, FD&amp;C Yellow #6 as coloring, and natural and artificial berry flavoring.</p>
<p>Chemically, dicyclomine hydrochloride is [bicyclohexyl]-1-carboxylic acid, 2-(diethylamino) ethyl ester, hydrochloride. Dicyclomine hydrochloride occurs as a fine, white, crystalline, practically odorless powder with a bitter taste. It is soluble in water, freely soluble in alcohol and chloroform, and very slightly soluble in ether. Its structural formula is as follows:</p>
<div class="Figure"><img alt="Image from Drug Label Content" src="http://dailymed.nlm.nih.gov/dailymed/image.cfm?setid=D59FA254-7959-47C9-BB77-AB7946A1A127&amp;name=dicyclomine-hydro-01.jpg"></div>
<p>C<span class="Sub">19</span>H<span class="Sub">35</span>NO<span class="Sub">2</span> • HCl      </p>
<p>M.W. 345.95</p>
</div>
<div class="Section" data-sectionCode="34090-1">
<a name="i4i_clinical_pharmacology_ID_F6069C64-3EE2-4F7E-9C0A-7B9B94BD491E"></a><a name="section-3"></a><p></p>
<h1>CLINICAL PHARMACOLOGY</h1>
<p class="First">Dicyclomine relieves smooth <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">muscle spasm</span> of the gastrointestinal tract. Animal studies indicate that this action is achieved via a dual mechanism: (1) a specific anticholinergic effect (antimuscarinic) at the acetylcholine-receptor sites with approximately 1/8 the milligram potency of atropine (<span class="Italics">in vitro</span>, guinea pig ileum): and (2) a direct effect upon smooth muscle (musculotropic) as evidenced by dicyclomine’s antagonism of bradykinin-and histamine-induced <span class="product-label-link" type="condition" conceptid="75635" conceptname="Cramp">spasms</span> of the isolated guinea pig ileum. Atropine did not affect responses to these two agonists. <span class="Italics">In vivo</span> studies in cats and dogs showed dicyclomine to be equally potent against acetylcholine (ACh)- or barium chloride (BaCl<span class="Sub">2</span>)-induced <span class="product-label-link" type="condition" conceptid="4091963" conceptname="Bowel spasm">intestinal spasm</span> while atropine was at least 200 times more potent against effects of ACh than BaCl<span class="Sub">2</span>. Tests for mydriatic effects in mice showed that dicyclomine was approximately 1/500 as potent as atropine; antisialagogue tests in rabbits showed dicyclomine to be 1/300 as potent as atropine. </p>
<p>In man, dicyclomine is rapidly absorbed after oral administration, reaching peak values within 60-90 minutes. The principal route of elimination is via the urine (79.5% of the dose). Excretion also occurs in the feces, but to a lesser extent (8.4%). Mean half-life of plasma elimination in one study was determined to be approximately 1.8 hours when plasma concentrations were measured for 9 hours after a single dose. In subsequent studies, plasma concentrations were followed for up to 24 hours after a single dose, showing a secondary phase of elimination with a somewhat longer half-life. Mean volume of distribution for a 20 mg oral dose is approximately 3.65 L/kg suggesting extensive distribution in tissues. </p>
<p>In controlled clinical trials involving over 100 patients who received drug, 82% of patients treated for functional bowel/<span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> with dicyclomine hydrochloride at initial doses of 160 mg daily (40 mg q.i.d.) demonstrated a favorable clinical response compared with 55% treated with placebo. (P&lt;0.05). In these trials, most of the side effects were typically anticholinergic in nature (see table) and were reported by 61% of the patients. </p>
<a name="ID_363D5DD1-68D4-4EC7-9FE2-945730D18D03"></a><table frame="box" width="0.000">
<col>
<col>
<col>
<tbody class="Headless">
<tr class="First">
<td class="Botrule Rrule" align="center" valign="top"><p class="First">Side Effects</p></td>
<td class="Botrule Rrule" align="center" valign="top">
<p class="First">Dicyclomine Hydrochloride</p>(40 mg q.i.d.) %</td>
<td class="Botrule" align="center" valign="top">
<p class="First">Placebo </p>
<p>%</p>
</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">Dry Mouth</span></td>
<td class="Botrule Rrule" align="center" valign="top">33</td>
<td class="Botrule" align="center" valign="top">5</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Dizziness</span></td>
<td class="Botrule Rrule" align="center" valign="top">29</td>
<td class="Botrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">Blurred Vision</span></td>
<td class="Botrule Rrule" align="center" valign="top">27</td>
<td class="Botrule" align="center" valign="top">2</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">Nausea</span></td>
<td class="Botrule Rrule" align="center" valign="top">14</td>
<td class="Botrule" align="center" valign="top">6</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">Lightheadedness</span></td>
<td class="Botrule Rrule" align="center" valign="top">11</td>
<td class="Botrule" align="center" valign="top">3</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">Drowsiness</span></td>
<td class="Botrule Rrule" align="center" valign="top">9</td>
<td class="Botrule" align="center" valign="top">1</td>
</tr>
<tr>
<td class="Botrule Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">Weakness</span></td>
<td class="Botrule Rrule" align="center" valign="top">7</td>
<td class="Botrule" align="center" valign="top">1</td>
</tr>
<tr class="Last">
<td class="Rrule" align="left" valign="top"><span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">Nervousness</span></td>
<td class="Rrule" align="center" valign="top">6</td>
<td class="Botrule" align="center" valign="top">2</td>
</tr>
</tbody>
</table>
<p>Nine percent (9%) of patients were discontinued from the drug because of one or more of these side effects (compared with 2% in the placebo group). In 41% of the patients with side effects, side effects disappeared or were tolerated at the 160 mg daily dose without reduction. A dose reduction from 160 mg daily to an average daily dose of 90 mg was required in 46% of the patients with side effects who then continued to experience a favorable clinical response; their side effects either disappeared or were tolerated. (See <a href="#i4i_adverse_effects_ID_6582D4FD-4E01-45EF-82E4-8712EFE8370A">ADVERSE REACTIONS</a>.) </p>
</div>
<div class="Section" data-sectionCode="34067-9">
<a name="i4i_indications_ID_03735193-223F-4A27-BAE7-799980C41238"></a><a name="section-4"></a><p></p>
<h1>INDICATIONS AND USAGE</h1>
<p class="First">Dicyclomine hydrochloride oral solution is indicated for the treatment of functional bowel/<span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span>.</p>
</div>
<div class="Section" data-sectionCode="34070-3">
<a name="i4i_contraindications_ID_667D3705-D2BC-4D3A-BFEF-FA8BDF91DED6"></a><a name="section-5"></a><p></p>
<h1>CONTRAINDICATIONS</h1>
<ol>
<li><span class="product-label-link" type="condition" conceptid="194406" conceptname="Urinary tract obstruction">Obstructive uropathy</span> </li>
<li>Obstructive disease of the gastrointestinal tract </li>
<li>Severe <span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">ulcerative colitis</span> (see <a href="#i4i_precautions_ID_5D9ABFC7-D193-47A6-B1DD-CB206C930986">PRECAUTIONS</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="30437" conceptname="Gastro-esophageal reflux disease with esophagitis">Reflux esophagitis</span> </li>
<li>Unstable cardiovascular status in acute <span class="product-label-link" type="condition" conceptid="437312" conceptname="Bleeding">hemorrhage</span> </li>
<li><span class="product-label-link" type="condition" conceptid="437541" conceptname="Glaucoma">Glaucoma</span> </li>
<li><span class="product-label-link" type="condition" conceptid="76685" conceptname="Myasthenia gravis">Myasthenia gravis</span> </li>
<li>Evidence of prior <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">hypersensitivity</span> to dicyclomine hydrochloride or other ingredients in this formulation </li>
<li>Infants less than 6 months of age (See <a href="#i4i_warnings_ID_4CD42CCF-51C5-4F54-BF09-C7F7A22393BF">WARNINGS</a> and <a href="#i4i_precautions_ID_5D9ABFC7-D193-47A6-B1DD-CB206C930986">PRECAUTIONS</a><span class="Bold">:</span><span class="Italics"><a href="#i4i_info_patients_ID_416B5390-D6C5-4E12-8658-F409958EA921">Information For Patients</a>.</span>) </li>
<li>Nursing Mothers (See <a href="#i4i_warnings_ID_4CD42CCF-51C5-4F54-BF09-C7F7A22393BF">WARNINGS</a> and <a href="#i4i_precautions_ID_5D9ABFC7-D193-47A6-B1DD-CB206C930986">PRECAUTIONS</a><span class="Bold">:</span><a href="#i4i_info_patients_ID_416B5390-D6C5-4E12-8658-F409958EA921">Information For Patients</a>) </li>
</ol>
</div>
<div class="Section" data-sectionCode="34071-1">
<a name="i4i_warnings_ID_4CD42CCF-51C5-4F54-BF09-C7F7A22393BF"></a><a name="section-6"></a><p></p>
<h1>WARNINGS</h1>
<p class="First">In the presence of a high environmental temperature <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span> can occur with drug use (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span> due to decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>). If symptoms occur, the drug should be discontinued and supportive measures instituted.</p>
<p><span class="product-label-link" type="condition" conceptid="80141" conceptname="Functional diarrhea">Diarrhea</span> may be an early symptom of incomplete <span class="product-label-link" type="condition" conceptid="193518" conceptname="Intestinal obstruction">intestinal obstruction</span>, especially in patients with ileostomy or colostomy. In this instance, treatment with this drug would be inappropriate and possibly harmful. </p>
<p>Dicyclomine hydrochloride oral solution may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. The patient should be warned not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery or performing hazardous work while taking this drug. </p>
<p><span class="product-label-link" type="condition" conceptid="436073" conceptname="Psychotic disorder">Psychosis</span> has been reported in sensitive individuals given anticholinergic drugs. CNS signs and symptoms include <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">confusion</span>, <span class="product-label-link" type="condition" conceptid="4011527" conceptname="Spatial disorientation">disorientation</span>, short-term <span class="product-label-link" type="condition" conceptid="439147" conceptname="Amnesia">memory loss</span>, <span class="product-label-link" type="condition" conceptid="433031" conceptname="Hallucinations">hallucinations</span>, <span class="product-label-link" type="condition" conceptid="4196636" conceptname="Dysarthria">dysarthria</span>, <span class="product-label-link" type="condition" conceptid="437584" conceptname="Ataxia">ataxia</span>, <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>, <span class="product-label-link" type="condition" conceptid="4142453" conceptname="Feeling high">euphoria</span>, decreased <span class="product-label-link" type="condition" conceptid="441542" conceptname="Anxiety">anxiety</span>, <span class="product-label-link" type="condition" conceptid="4223659" conceptname="Fatigue">fatigue</span>, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>, <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">agitation</span> and mannerisms, and <span class="product-label-link" type="condition" conceptid="4154304" conceptname="Inappropriate affect">inappropriate affect</span>. </p>
<p>These CNS signs and symptoms usually resolve within 12 to 24 hours after discontinuation of the drug. </p>
<p>There are reports that administration of dicyclomine hydrochloride oral soution to infants has been followed by serious respiratory symptoms (<span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">dyspnea</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">shortness of breath</span>, <span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">breathlessness</span>, respiratory collapse, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="4139960" conceptname="Strangulation">asphyxia</span>), <span class="product-label-link" type="condition" conceptid="377091" conceptname="Seizure">seizures</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, pulse rate fluctuations, muscular <span class="product-label-link" type="condition" conceptid="4002033" conceptname="Muscle relaxation">hypotonia</span>, and <span class="product-label-link" type="condition" conceptid="380834" conceptname="Coma">coma</span>. <span class="product-label-link" type="condition" conceptid="4306655" conceptname="Death">Death</span> has been reported. No causal relationship between these effects observed in infants and dicyclomine administration has been established. DICYCLOMINE HYDROCHLORIDE ORAL SOLUTION  IS CONTRAINDICATED IN INFANTS LESS THAN 6 MONTHS OF AGE AND IN NURSING MOTHERS. (See <span class="Bold"><a href="#i4i_contraindications_ID_667D3705-D2BC-4D3A-BFEF-FA8BDF91DED6">CONTRAINDICATIONS</a></span> and <span class="Bold"><a href="#i4i_precautions_ID_5D9ABFC7-D193-47A6-B1DD-CB206C930986">PRECAUTIONS</a>: </span><a href="#i4i_nursing_mothers_ID_B6DA3883-768D-4735-A829-35C8E69107A0">Nursing Mothers</a> and <a href="#i4i_pediatric_use_ID_54708281-C090-4DF8-9009-561C1EA1D6B2">Pediatric Use</a>.)</p>
<p>Safety and efficacy of dicyclomine hydrochloride in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42232-9">
<a name="i4i_precautions_ID_5D9ABFC7-D193-47A6-B1DD-CB206C930986"></a><a name="section-7"></a><p></p>
<h1>PRECAUTIONS</h1>
<div class="Section" data-sectionCode="34072-9">
<a name="i4i_precautions_general_ID_6B968812-FF1D-451F-9F05-9AC02E15C256"></a><a name="section-7.1"></a><p></p>
<h2>General</h2>
<p class="First">Use with caution in patients with:</p>
<ol>
<li><span class="product-label-link" type="condition" conceptid="4080146" conceptname="Autonomic neuropathy">Autonomic neuropathy</span> </li>
<li>Hepatic or <span class="product-label-link" type="condition" conceptid="198124" conceptname="Kidney disease">renal disease</span> </li>
<li><span class="product-label-link" type="condition" conceptid="81893" conceptname="Ulcerative colitis">Ulcerative colitis</span>-large doses may suppress intestinal motility to the point of producing a <span class="product-label-link" type="condition" conceptid="192357" conceptname="Paralytic ileus">paralytic ileus</span> and the use of this drug may precipitate or aggravate the serious complication of toxic <span class="product-label-link" type="condition" conceptid="198465" conceptname="Megacolon, not Hirschsprung's">megacolon</span> (see <a href="#i4i_contraindications_ID_667D3705-D2BC-4D3A-BFEF-FA8BDF91DED6">CONTRAINDICATIONS</a>) </li>
<li><span class="product-label-link" type="condition" conceptid="4142479" conceptname="Hyperthyroidism">Hyperthyroidism</span> </li>
<li><span class="product-label-link" type="condition" conceptid="316866" conceptname="Hypertensive disorder">Hypertension</span> </li>
<li>Coronary heart disease </li>
<li><span class="product-label-link" type="condition" conceptid="319835" conceptname="Congestive heart failure">Congestive heart failure</span> </li>
<li>Cardiac <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachyarrhythmia</span> </li>
<li><span class="product-label-link" type="condition" conceptid="4224004" conceptname="Hiatal hernia">Hiatal hernia</span> (see <span class="Bold"><a href="#i4i_contraindications_ID_667D3705-D2BC-4D3A-BFEF-FA8BDF91DED6">CONTRAINDICATIONS</a></span>: <span class="product-label-link" type="condition" conceptid="30437" conceptname="Gastro-esophageal reflux disease with esophagitis">reflux esophagitis</span>) </li>
<li>Known or suspected <span class="product-label-link" type="condition" conceptid="198803" conceptname="Benign prostatic hyperplasia">prostatic hypertrophy</span>. </li>
</ol>
<p>Investigate any <span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span> before administration of dicyclomine hydrochloride, since it may increase the heart rate. </p>
<p>With overdosage, a curare-like action may occur (i.e., <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> leading to <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span> and possible <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>).</p>
</div>
<div class="Section" data-sectionCode="34076-0">
<a name="i4i_info_patients_ID_416B5390-D6C5-4E12-8658-F409958EA921"></a><a name="section-7.2"></a><p></p>
<h2>Information For Patients</h2>
<p class="First">Dicyclomine hydrochloride may produce <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span> or <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>. The patient should be warned not to engage in activities requiring mental alertness, such as operating a motor vehicle or other machinery or to perform hazardous work while taking this drug. </p>
<p>Dicyclomine hydrochloride is contraindicated in infants less than 6 months of age and in nursing mothers. (See <a href="#i4i_contraindications_ID_667D3705-D2BC-4D3A-BFEF-FA8BDF91DED6">CONTRAINDICATIONS</a>, <a href="#i4i_warnings_ID_4CD42CCF-51C5-4F54-BF09-C7F7A22393BF">WARNINGS</a>, and <a href="#i4i_precautions_ID_5D9ABFC7-D193-47A6-B1DD-CB206C930986">PRECAUTIONS</a>: <a href="#i4i_nursing_mothers_ID_B6DA3883-768D-4735-A829-35C8E69107A0">Nursing Mothers</a> and <a href="#i4i_pediatric_use_ID_54708281-C090-4DF8-9009-561C1EA1D6B2">Pediatric Use</a>). </p>
<p>In the presence of a high environmental temperature, <span class="product-label-link" type="condition" conceptid="437744" conceptname="Heat exhaustion">heat prostration</span> can occur with drug use (<span class="product-label-link" type="condition" conceptid="437663" conceptname="Fever">fever</span> and <span class="product-label-link" type="condition" conceptid="4181404" conceptname="Heat stroke">heat stroke</span> due to decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>). If symptoms occur, the drug should be discontinued and a physician contacted.</p>
</div>
<div class="Section" data-sectionCode="34073-7">
<a name="i4i_drug_interaction_ID_91D4F3A0-7D46-4C80-B52A-0B425871765C"></a><a name="section-7.3"></a><p></p>
<h2>Drug Interactions</h2>
<p class="First">The following agents may increase certain actions or side effects of anticholinergic drugs: amantadine, antiarrhythmic agents of Class I (e.g., quinidine), antihistamines, antipsychotic agents (e.g., phenothiazines), benzodiazepines, MAO inhibitors, narcotic analgesics (e.g., meperidine), nitrates and nitrites, sympathomimetic agents, tricyclic antidepressants, and other drugs having anticholinergic activity. </p>
<p>Anticholinergics antagonize the effects of antiglaucoma agents. Anticholinergic drugs in the presence of <span class="product-label-link" type="condition" conceptid="4011560" conceptname="Raised intraocular pressure">increased intraocular pressure</span> may be hazardous when taken concurrently with agents such as corticosteroids. (See also <a href="#i4i_contraindications_ID_667D3705-D2BC-4D3A-BFEF-FA8BDF91DED6">CONTRAINDICATIONS</a>.) </p>
<p>Anticholinergic agents may affect gastrointestinal absorption of various drugs, such as slowly dissolving dosage forms of digoxin; increased serum digoxin concentrations may result. Anticholinergic drugs may antagonize the effects of the drugs that alter gastrointestinal motility, such as metoclopramide. Because antacids may interfere with the absorption of anticholinergic agents, simultaneous use of these drugs should be avoided. </p>
<p>The inhibiting effects of anticholinergic drugs on gastric hydrochloric acid secretion are antagonized by agents used to treat <span class="product-label-link" type="condition" conceptid="193804" conceptname="Achlorhydria">achlorhydria</span> and those used to test gastric secretion.</p>
</div>
<div class="Section" data-sectionCode="34083-6">
<a name="i4i_carcinogenesis_mutagenesis_fertility_ID_03CD498E-E0C1-428D-85D3-8A6252230880"></a><a name="section-7.4"></a><p></p>
<h2>Carcinogenesis, Mutagenesis, Impairment of Fertility</h2>
<p class="First">There are no known human data on long-term potential for carcinogenicity or mutagenicity.</p>
<p>Long-term studies in animals to determine carcinogenic potential are not known to have been conducted. </p>
<p>In studies in rats at doses of up to 100 mg/kg/day, dicyclomine hydrochloride produced no deleterious effects on breeding, conception, or parturition.</p>
</div>
<div class="Section" data-sectionCode="42228-7">
<a name="i4i_pregnancy_ID_9CBE8D84-8A20-4DFB-A80E-E1D465685094"></a><a name="section-7.5"></a><p></p>
<h2>Pregnancy</h2>
</div>
<div class="Section" data-sectionCode="34077-8">
<a name="i4i_teratogenic_ID_FB957170-7617-436F-932C-AD30DBC4F9EA"></a><a name="section-7.6"></a><p></p>
<h2>Teratogenic Effects: Pregnancy Category B </h2>
<p class="First">Reproduction studies have been performed in rats and rabbits at doses up to 33 times the maximum recommended human dose based on 160 mg/day (3 mg/kg) and have revealed no evidence of impaired fertility or harm to the fetus due to dicyclomine. Epidemiologic studies in pregnant women with products containing dicyclomine hydrochloride (at doses up to 40 mg/day) have not shown that dicyclomine increases the risk of fetal abnormalities if administered during the first trimester of pregnancy. There are, however, no adequate and well-controlled studies in pregnant women at the recommended doses (80-l60 mg/day). Because animal reproduction studies are not always predictive of human response, dicyclomine hydrochloride as indicated for functional bowel/<span class="product-label-link" type="condition" conceptid="75576" conceptname="Irritable bowel syndrome">irritable bowel syndrome</span> should be used during pregnancy only if clearly needed.</p>
</div>
<div class="Section" data-sectionCode="34080-2">
<a name="i4i_nursing_mothers_ID_B6DA3883-768D-4735-A829-35C8E69107A0"></a><a name="section-7.7"></a><p></p>
<h2>Nursing Mothers</h2>
<p class="First">Since dicyclomine hydrochloride has been reported to be excreted in human milk, DICYCLOMINE HYDROCHLORIDE IS CONTRAINDICATED IN NURSING MOTHERS. (See <a href="#i4i_contraindications_ID_667D3705-D2BC-4D3A-BFEF-FA8BDF91DED6">CONTRAINDICATIONS</a>, <a href="#i4i_warnings_ID_4CD42CCF-51C5-4F54-BF09-C7F7A22393BF">WARNINGS</a>, <a href="#i4i_precautions_ID_5D9ABFC7-D193-47A6-B1DD-CB206C930986">PRECAUTIONS</a>: <a href="#i4i_pediatric_use_ID_54708281-C090-4DF8-9009-561C1EA1D6B2">Pediatric Use</a> and <a href="#i4i_adverse_effects_ID_6582D4FD-4E01-45EF-82E4-8712EFE8370A">ADVERSE REACTIONS</a>.)</p>
</div>
<div class="Section" data-sectionCode="34081-0">
<a name="i4i_pediatric_use_ID_54708281-C090-4DF8-9009-561C1EA1D6B2"></a><a name="section-7.8"></a><p></p>
<h2>Pediatric Use</h2>
<p class="First">(See <a href="#i4i_contraindications_ID_667D3705-D2BC-4D3A-BFEF-FA8BDF91DED6">CONTRAINDICATIONS</a>, <a href="#i4i_warnings_ID_4CD42CCF-51C5-4F54-BF09-C7F7A22393BF">WARNINGS</a>, and <a href="#i4i_precautions_ID_5D9ABFC7-D193-47A6-B1DD-CB206C930986">PRECAUTIONS</a>: <a href="#i4i_nursing_mothers_ID_B6DA3883-768D-4735-A829-35C8E69107A0">Nursing Mothers</a>). DICYCLOMINE HYDROCHLORIDE IS CONTRAINDICATED IN INFANTS LESS THAN 6 MONTHS OF AGE.</p>
<p>Safety and effectiveness in pediatric patients have not been established.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_9ECEDEBF-CA22-4468-87BA-6CCB192586A4"></a><a name="section-7.9"></a><p></p>
<h2>Geriatric Use</h2>
<p class="First">Clinical studies of dicyclomine hydrochloride oral solution did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3117">DOSAGE AND ADMINISTRATION</a>)<br></p>
<p>This drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with <span class="product-label-link" type="condition" conceptid="4030518" conceptname="Renal impairment">impaired renal function</span>. Because elderly patients are more likely to have decreased renal function, care should be taken in dose selection, and it may be useful to monitor renal function.</p>
</div>
</div>
<div class="Section" data-sectionCode="34084-4">
<a name="i4i_adverse_effects_ID_6582D4FD-4E01-45EF-82E4-8712EFE8370A"></a><a name="section-8"></a><p></p>
<h1>ADVERSE REACTIONS</h1>
<p class="First">Controlled clinical trials have provided frequency information for reported adverse effects of dicyclomine hydrochloride listed in a decreasing order of frequency. (See <a href="#i4i_clinical_pharmacology_ID_F6069C64-3EE2-4F7E-9C0A-7B9B94BD491E">CLINICAL PHARMACOLOGY</a>.)</p>
<p>Not all of the following adverse reactions have been reported with dicyclomine hydrochloride. Adverse reactions are included here that have been reported for pharmacologically similar drugs with anticholinergic/antispasmodic action. </p>
<p><span class="Italics">Gastrointestinal<span class="Bold">:</span></span> <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>, <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>, <span class="product-label-link" type="condition" conceptid="75860" conceptname="Constipation">constipation</span>. <span class="product-label-link" type="condition" conceptid="4218984" conceptname="Abdominal distension">bloated feeling</span>, <span class="product-label-link" type="condition" conceptid="200219" conceptname="Abdominal pain">abdominal pain</span>, <span class="product-label-link" type="condition" conceptid="4289517" conceptname="Loss of taste">taste loss</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">anorexia</span>. </p>
<p><span class="Italics">Central Nervous System<span class="Bold">:</span></span> <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>, <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">lightheadedness</span>, <span class="product-label-link" type="condition" conceptid="4193492" conceptname="Acroparesthesia">tingling</span>, <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>, <span class="product-label-link" type="condition" conceptid="4196193" conceptname="Drowsiness">drowsiness</span>, <span class="product-label-link" type="condition" conceptid="437113" conceptname="Asthenia">weakness</span>, <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span>, <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span>, <span class="product-label-link" type="condition" conceptid="381273" conceptname="Confusional state">mental confusion</span> and/or <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span> (especially in elderly persons), <span class="product-label-link" type="condition" conceptid="4047115" conceptname="Oral dyskinesia">dyskinesia</span>, <span class="product-label-link" type="condition" conceptid="4061577" conceptname="Lethargy">lethargy</span>, <span class="product-label-link" type="condition" conceptid="135360" conceptname="Syncope">syncope</span>, speech disturbance, <span class="product-label-link" type="condition" conceptid="436962" conceptname="Insomnia">insomnia</span>.</p>
<p><span class="Italics">Ophthalmologic: </span><span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, <span class="product-label-link" type="condition" conceptid="373474" conceptname="Diplopia">diplopia</span>, <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">mydriasis</span>, <span class="product-label-link" type="condition" conceptid="375263" conceptname="Cycloplegia">cycloplegia</span>, increased ocular <span class="product-label-link" type="condition" conceptid="4200706" conceptname="Tension">tension</span> </p>
<p><span class="Italics">Dermatologic/Allergic:</span> <span class="product-label-link" type="condition" conceptid="140214" conceptname="Eruption">rash</span>, <span class="product-label-link" type="condition" conceptid="139900" conceptname="Urticaria">urticaria</span>, <span class="product-label-link" type="condition" conceptid="4302654" conceptname="Itching">itching</span>, and other dermal manifestations; severe <span class="product-label-link" type="condition" conceptid="4084167" conceptname="Acute allergic reaction">allergic reaction</span> or drug idiosyncrasies including <span class="product-label-link" type="condition" conceptid="441202" conceptname="Anaphylaxis">anaphylaxis</span>. </p>
<p><span class="Italics">Genitourinary: </span><span class="product-label-link" type="condition" conceptid="201688" conceptname="Delay when starting to pass urine">urinary hesitancy</span>, <span class="product-label-link" type="condition" conceptid="192450" conceptname="Retention of urine">urinary retention</span> </p>
<p><span class="Italics">Cardiovascular: </span><span class="product-label-link" type="condition" conceptid="315643" conceptname="Tachyarrhythmia">tachycardia</span>. <span class="product-label-link" type="condition" conceptid="315078" conceptname="Palpitations">palpitations</span> </p>
<p><span class="Italics">Respiratory: </span><span class="product-label-link" type="condition" conceptid="312437" conceptname="Dyspnea">Dyspnea</span>, <span class="product-label-link" type="condition" conceptid="321689" conceptname="Apnea">apnea</span>, <span class="product-label-link" type="condition" conceptid="4139960" conceptname="Strangulation">asphyxia</span> (see <span class="Bold"><a href="#i4i_warnings_ID_4CD42CCF-51C5-4F54-BF09-C7F7A22393BF">WARNINGS</a></span>) </p>
<p><span class="Italics">Other: </span>decreased <span class="product-label-link" type="condition" conceptid="138565" conceptname="Hyperhidrosis">sweating</span>, <span class="product-label-link" type="condition" conceptid="4195085" conceptname="Nasal congestion">nasal stuffiness</span> or congestion, <span class="product-label-link" type="condition" conceptid="4328356" conceptname="Sneezing">sneezing</span>, throat congestion, <span class="product-label-link" type="condition" conceptid="4216771" conceptname="Impotence">impotence</span>, suppression of lactation (see <a href="#i4i_precautions_ID_5D9ABFC7-D193-47A6-B1DD-CB206C930986">PRECAUTIONS</a><span class="Bold">:</span><a href="#i4i_nursing_mothers_ID_B6DA3883-768D-4735-A829-35C8E69107A0">Nursing Mothers</a>)</p>
</div>
<div class="Section" data-sectionCode="42227-9">
<a name="i4i_abuse_dependence_ID_10CB50FA-5C17-4BAC-9B83-71693D51B795"></a><a name="section-9"></a><p></p>
<h1>DRUG ABUSE AND <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">DEPENDENCE</span></h1>
<p class="First">Abuse of and/or <span class="product-label-link" type="condition" conceptid="4113279" conceptname="Dependence">dependence</span> on dicyclomine for anticholinergic effects have been rarely reported.</p>
</div>
<div class="Section" data-sectionCode="34088-5">
<a name="i4i_overdosage_ID_B7E7872B-A42A-46CB-9878-3D83CF9269E4"></a><a name="section-10"></a><p></p>
<h1>OVERDOSAGE</h1>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_35059D48-5911-48D4-8642-0964B78A3DDA"></a><a name="section-10.1"></a><p></p>
<h2>Signs and Symptoms</h2>
<p class="First">The signs and symptoms of overdosage are <span class="product-label-link" type="condition" conceptid="378253" conceptname="Headache">headache</span>; <span class="product-label-link" type="condition" conceptid="31967" conceptname="Nausea">nausea</span>; <span class="product-label-link" type="condition" conceptid="441408" conceptname="Vomiting">vomiting</span>; <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>; <span class="product-label-link" type="condition" conceptid="4290615" conceptname="Dilated pupil">dilated pupils</span>; hot, <span class="product-label-link" type="condition" conceptid="4039266" conceptname="Dry skin">dry skin</span>; <span class="product-label-link" type="condition" conceptid="4223938" conceptname="Dizziness">dizziness</span>; dryness of the mouth; difficulty in swallowing; and CNS stimulation. A curare-like action may occur (i.e., <span class="product-label-link" type="condition" conceptid="4205421" conceptname="Neuromuscular block">neuromuscular blockade</span> leading to <span class="product-label-link" type="condition" conceptid="79908" conceptname="Muscle weakness">muscular weakness</span> and possible <span class="product-label-link" type="condition" conceptid="440377" conceptname="Paralysis">paralysis</span>). </p>
<p>A 37-year-old female reported <span class="product-label-link" type="condition" conceptid="4151171" conceptname="Numbness of limbs">numbness</span> on the left side, <span class="product-label-link" type="condition" conceptid="260427" conceptname="Common cold">cold</span> fingertips, <span class="product-label-link" type="condition" conceptid="4079185" conceptname="Hazy vision">blurred vision</span>, abdominal and <span class="product-label-link" type="condition" conceptid="4090433" conceptname="Flank pain">flank pain</span>, <span class="product-label-link" type="condition" conceptid="442165" conceptname="Loss of appetite">decreased appetite</span>, <span class="product-label-link" type="condition" conceptid="4226991" conceptname="Aptyalism">dry mouth</span>, and <span class="product-label-link" type="condition" conceptid="436817" conceptname="Feeling nervous">nervousness</span> following ingestion of 320 mg daily (four 20 mg tablets QID) for four days. These events resolved after discontinuing the dicyclomine.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_41A2E33F-CF70-4E46-A7C4-AD718CC7A4E4"></a><a name="section-10.2"></a><p></p>
<h2>Oral LD<span class="Sub">50</span>
</h2>
<p class="First">The acute oral LD<span class="Sub">50</span> of the drug is 625 mg/kg in mice. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_F64117C7-4FB3-47AD-A40C-BAECA76B1DC7"></a><a name="section-10.3"></a><p></p>
<h2>Minimum Human Lethal Dose/Maximum Human Dose Recorded</h2>
<p class="First">The amount of drug in a single dose that is ordinarily associated with symptoms of overdosage or that is likely to be life threatening, has not been defined. The maximum human oral dose recorded was 600 mg by mouth in a 10-month-old child and approximately 1500 mg in an adult, each of whom survived. </p>
<p>In three of the infants who died following administration of dicyclomine hydrochloride (see <a href="#i4i_warnings_ID_4CD42CCF-51C5-4F54-BF09-C7F7A22393BF">WARNINGS</a>), the blood concentrations of drug were 200, 220, and 505 ng/mL, respectively. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_4ED5A990-3EBB-4C8B-B7CC-F51DC443F936"></a><a name="section-10.4"></a><p></p>
<h2>Dialysis</h2>
<p class="First">It is not known if dicyclomine hydrochoride is dialyzable. </p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_1579E55D-C328-4252-B884-753144EAF3F1"></a><a name="section-10.5"></a><p></p>
<h2>Treatment</h2>
<p class="First">Treatment should consist of gastric lavage, emetics, and activated charcoal. Sedatives (e.g., short-acting barbiturates, benzodiazepines) may be used for management of overt signs of <span class="product-label-link" type="condition" conceptid="436087" conceptname="Excitement">excitement</span>. If indicated, an appropriate parenteral cholinergic agent may be used as an antidote.</p>
</div>
</div>
<div class="Section" data-sectionCode="34068-7">
<a name="i4i_dosage_admin_ID_A5613FF6-F223-4F9F-935C-76EB1B154C46"></a><a name="section-11"></a><p></p>
<h1>DOSAGE AND ADMINISTRATION</h1>
<p class="First">DOSAGE MUST BE ADJUSTED TO INDIVIDUAL PATIENT NEEDS. (See <a href="#i4i_clinical_pharmacology_ID_F6069C64-3EE2-4F7E-9C0A-7B9B94BD491E">CLINICAL PHARMACOLOGY</a>.) </p>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_391C9CC7-3C05-4194-8905-6C4B69A9B3F0"></a><a name="section-11.1"></a><p></p>
<h2>Adults-Oral</h2>
<p class="First">The only oral dose clearly shown to be effective is 160 mg per day (in 4 equally divided doses). Since this dose is associated with a significant incidence of side effects, it is prudent to begin with 80 mg per day (in 4 equally divided doses). Depending upon the patient’s response during the first week of therapy, the dose should be increased to 160 mg per day unless side effects limit dosage escalation.</p>
<p>If efficacy is not achieved within 2 weeks or side effects require doses below 80 mg per day, the drug should be discontinued. Documented safety data are not available for doses above 80 mg daily for periods longer than 2 weeks.</p>
</div>
<div class="Section" data-sectionCode="42229-5">
<a name="i4i_section_ID_4F061A1C-D2AD-4F51-BAEB-CCAE4CCD4B28"></a><a name="section-11.2"></a><p></p>
<h2>Elderly </h2>
<p class="First">In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy. (See <a href="http://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?id=3117">Precautions: Geriatric Use</a>)<br></p>
</div>
</div>
<div class="Section" data-sectionCode="34069-5">
<a name="i4i_how_supplied_ID_A456F6AA-10EF-44B1-B8BB-6C2DCC45EAB6"></a><a name="section-12"></a><p></p>
<h1>HOW SUPPLIED</h1>
<p class="First">Dicyclomine Hydrochloride Oral Solution USP is supplied as a pink, clear, berry-flavored syrup in bottles of 473 mL (16 fl oz).</p>
<div class="Section" data-sectionCode="44425-7">
<a name="i4i_section_ID_4076FC0C-4C6E-4F66-BA47-72F9B4BC799C"></a><a name="section-12.1"></a><p></p>
<h2>STORAGE: </h2>
<p class="First">Store at 20° to 25°C (68° to 77°F). [see USP Controlled Room Temperature]. </p>
<p>Dispense in a tight container with a child-resistant closure.</p>
<p>Manufactured by:</p>
<p><span class="Bold">MIKART, INC.</span></p>
<p>Atlanta, GA 30318</p>
<p>Code 814Z00                                                                                             </p>
<p>Rev 03/08</p>
</div>
</div>
</div>
<div class="DataElementsTables">
<table class="contentTablePetite" cellSpacing="0" cellPadding="3" width="100%"><tbody>
<tr><td class="contentTableTitle">
<strong>DICYCLOMINE HYDROCHLORIDE 		
					</strong><br><span class="contentTableReg">dicyclomine hydrochloride solution</span>
</td></tr>
<tr><td><table width="100%" cellpadding="5" cellspacing="0" class="formTablePetite">
<tr><td colspan="4" class="formHeadingTitle">Product Information</td></tr>
<tr class="formTableRowAlt">
<td class="formLabel">Product Type</td>
<td class="formItem">HUMAN PRESCRIPTION DRUG LABEL</td>
<td class="formLabel">Item Code (Source)</td>
<td class="formItem">NDC:46672-630</td>
</tr>
<tr class="formTableRow">
<td width="30%" class="formLabel">Route of Administration</td>
<td class="formItem">ORAL</td>
<td width="30%" class="formLabel">DEA Schedule</td>
<td class="formItem">    
							</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="3" class="formHeadingTitle">Active Ingredient/Active Moiety</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Basis of Strength</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem">
<strong>dicyclomine hydrochloride</strong> (dicyclomine) </td>
<td class="formItem"></td>
<td class="formItem">10 mg  in 5 mL</td>
</tr>
</table></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="2" class="formHeadingTitle">Inactive Ingredients</td></tr>
<tr>
<th class="formTitle" scope="col">Ingredient Name</th>
<th class="formTitle" scope="col">Strength</th>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>D&amp;C Red #33</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Blue #1</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>FD&amp;C Red #40</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>FD&amp;C Yellow #6</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>glycerin</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>methylparaben</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>propylene glycol</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>water</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRowAlt">
<td class="formItem"><strong>sorbitol solution</strong></td>
<td class="formItem"> </td>
</tr>
<tr class="formTableRow">
<td class="formItem"><strong>sucrose</strong></td>
<td class="formItem"> </td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td><table width="100%" cellpadding="3" cellspacing="0" class="formTablePetite">
<tr><td colspan="5" class="formHeadingTitle">Packaging</td></tr>
<tr>
<th scope="col" width="1" class="formTitle">#</th>
<th scope="col" class="formTitle">Item Code</th>
<th scope="col" class="formTitle">Package Description</th>
<th scope="col" class="formTitle">Marketing Start Date</th>
<th scope="col" class="formTitle">Marketing End Date</th>
</tr>
<tr class="formTableRowAlt">
<th scope="row" class="formItem">1</th>
<td class="formItem">NDC:46672-630-16</td>
<td class="formItem">473 mL in 1 BOTTLE</td>
<td class="formItem"></td>
<td class="formItem"></td>
</tr>
</table></td></tr>
<tr><td></td></tr>
<tr><td class="normalizer"></td></tr>
</tbody></table>
<table width="100%" cellpadding="3" cellspacing="0" class="formTableMorePetite"><tr><td colspan="4" class="formHeadingReg">
<span class="formHeadingTitle">Labeler - </span>MIKART, INC.</td></tr></table>
</div>
<p><div class="EffectiveDate">Revised: 8/2008<div class="DocumentMetadata">
<div>
<a href="javascript:toggleMixin();">Document Id: </a>D4919AF8-A464-0864-5A9B-79DFAA57DA66</div>
<div>Set id: D59FA254-7959-47C9-BB77-AB7946A1A127</div>
<div>Version: 1</div>
<div>Effective Time: 20080813</div>
</div>
</div> <div class="DistributorName">MIKART, INC.</div></p>
</body></html>
